Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05080166 · ClinicalTrials.gov registry record · NA
UPLYFT For Lymphoma Survivors
A NA study of Lymphoma and Survivorship, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT05080166: Recruiting NA study of Lymphoma and Survivorship, sponsored by Dana-Farber Cancer Institute.
NCT05080166 is a NA study of Lymphoma and Survivorship that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 74 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05080166, a NA study of Lymphoma and Survivorship, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.
Primary Outcome
Proportion of eligible patients approached that enroll in the study.
Conditions Studied
Interventions
- OTHER Interview with Clinicians
- OTHER Field Test of UPLYFT with Lymphoma Survivors
- BEHAVIORAL Pilot of UPLYFT with Lymphoma Survivors
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2022-02-08 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
What NCT05080166 shows while recruiting
NCT05080166 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Interview with Clinicians is the first listed.
NCT05080166 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05080166 about?
NCT05080166 is a clinical study titled "UPLYFT For Lymphoma Survivors". The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivor...
What is the current status of trial NCT05080166?
This trial is currently recruiting. It is a NA study. The enrollment target is 74 participants. The study started on 2022-02-08. Estimated completion is 2026-08-31.
What conditions does trial NCT05080166 study?
This clinical trial studies the following conditions: Lymphoma, Survivorship.
What interventions are being tested in trial NCT05080166?
The interventions under investigation include: Interview with Clinicians (OTHER), Field Test of UPLYFT with Lymphoma Survivors (OTHER), Pilot of UPLYFT with Lymphoma Survivors (BEHAVIORAL).
Who is sponsoring clinical trial NCT05080166?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05080166 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05080166's enrollment target sits among peer trials
74 113th of 299 higher than 186 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI